 Brooklyn Immuno Therapeutics Inc. NYSE: BTX shares are soaring Friday. The stock is likely continuing its run after the company paid 1 million towards the acquisition of a license for Factor Biosciences and Novellus mRNA gene editing and cell therapies technology. 